Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 206

1.

Partnering to fight malaria in India: Past, present and future.

Samby K, Ramachandruni H, Banerji J, Burrows JN, Daumerie PG, Hooft van Huijsduijnen RAM, Duparc S, Wells TNC.

J Vector Borne Dis. 2019 Jan-Mar;56(1):15-24. doi: 10.4103/0972-9062.257769. Review.

2.

Novel 1-Methyl-1 H-pyrazole-5-carboxamide Derivatives with Potent Anthelmintic Activity.

Le TG, Kundu A, Ghoshal A, Nguyen NH, Preston S, Jiao Y, Ruan B, Xue L, Huang F, Keiser J, Hofmann A, Chang BCH, Garcia-Bustos J, Wells TNC, Palmer MJ, Jabbar A, Gasser RB, Baell JB.

J Med Chem. 2019 Apr 11;62(7):3367-3380. doi: 10.1021/acs.jmedchem.8b01790. Epub 2019 Mar 28.

PMID:
30875218
3.

Structure-Activity Relationship Studies of Tolfenpyrad Reveal Subnanomolar Inhibitors of Haemonchus contortus Development.

Le TG, Kundu A, Ghoshal A, Nguyen NH, Preston S, Jiao Y, Ruan B, Xue L, Huang F, Keiser J, Hofmann A, Chang BCH, Garcia-Bustos J, Wells TNC, Palmer MJ, Jabbar A, Gasser RB, Baell JB.

J Med Chem. 2019 Jan 24;62(2):1036-1053. doi: 10.1021/acs.jmedchem.8b01789. Epub 2019 Jan 7.

PMID:
30571110
4.

A discovery and development roadmap for new endectocidal transmission-blocking agents in malaria.

Burrows J, Slater H, Macintyre F, Rees S, Thomas A, Okumu F, Hooft van Huijsduijnen R, Duparc S, Wells TNC.

Malar J. 2018 Dec 10;17(1):462. doi: 10.1186/s12936-018-2598-5. Review.

5.

Optimization of Novel 1-Methyl-1 H-Pyrazole-5-carboxamides Leads to High Potency Larval Development Inhibitors of the Barber's Pole Worm.

Le TG, Kundu A, Ghoshal A, Nguyen NH, Preston S, Jiao Y, Ruan B, Xue L, Huang F, Keiser J, Hofmann A, Chang BCH, Garcia-Bustos J, Jabbar A, Wells TNC, Palmer MJ, Gasser RB, Baell JB.

J Med Chem. 2018 Dec 13;61(23):10875-10894. doi: 10.1021/acs.jmedchem.8b01544. Epub 2018 Nov 29.

PMID:
30403349
6.

Repurposing of an old drug: In vitro and in vivo efficacies of buparvaquone against Echinococcus multilocularis.

Rufener R, Dick L, D'Ascoli L, Ritler D, Hizem A, Wells TNC, Hemphill A, Lundström-Stadelmann B.

Int J Parasitol Drugs Drug Resist. 2018 Dec;8(3):440-450. doi: 10.1016/j.ijpddr.2018.10.011. Epub 2018 Oct 31.

7.

Injectable anti-malarials revisited: discovery and development of new agents to protect against malaria.

Macintyre F, Ramachandruni H, Burrows JN, Holm R, Thomas A, Möhrle JJ, Duparc S, Hooft van Huijsduijnen R, Greenwood B, Gutteridge WE, Wells TNC, Kaszubska W.

Malar J. 2018 Nov 1;17(1):402. doi: 10.1186/s12936-018-2549-1. Review.

8.

The antimalarial pipeline.

Hooft van Huijsduijnen R, Wells TN.

Curr Opin Pharmacol. 2018 Oct;42:1-6. doi: 10.1016/j.coph.2018.05.006. Epub 2018 May 31. Review.

PMID:
29860174
9.

Macrovipecetin, a C-type lectin from Macrovipera lebetina venom, inhibits proliferation migration and invasion of SK-MEL-28 human melanoma cells and enhances their sensitivity to cisplatin.

Hammouda MB, Riahi-Chebbi I, Souid S, Othman H, Aloui Z, Srairi-Abid N, Karoui H, Gasmi A, Magnenat EM, Wells TNC, Clemetson KJ, Rodríguez-López JN, Essafi-Benkhadir K.

Biochim Biophys Acta Gen Subj. 2018 Mar;1862(3):600-614. doi: 10.1016/j.bbagen.2017.11.019. Epub 2017 Nov 28.

PMID:
29196192
10.

malERA: An updated research agenda for malaria elimination and eradication.

Rabinovich RN, Drakeley C, Djimde AA, Hall BF, Hay SI, Hemingway J, Kaslow DC, Noor A, Okumu F, Steketee R, Tanner M, Wells TNC, Whittaker MA, Winzeler EA, Wirth DF, Whitfield K, Alonso PL.

PLoS Med. 2017 Nov 30;14(11):e1002456. doi: 10.1371/journal.pmed.1002456. eCollection 2017 Nov. Review.

11.

Malaria.

Phillips MA, Burrows JN, Manyando C, van Huijsduijnen RH, Van Voorhis WC, Wells TNC.

Nat Rev Dis Primers. 2017 Aug 3;3:17050. doi: 10.1038/nrdp.2017.50. Review.

PMID:
28770814
12.

Screening of the 'Stasis Box' identifies two kinase inhibitors under pharmaceutical development with activity against Haemonchus contortus.

Jiao Y, Preston S, Koehler AV, Stroehlein AJ, Chang BCH, Simpson KJ, Cowley KJ, Palmer MJ, Laleu B, Wells TNC, Jabbar A, Gasser RB.

Parasit Vectors. 2017 Jul 5;10(1):323. doi: 10.1186/s13071-017-2246-x.

13.

Assessing the anthelmintic activity of pyrazole-5-carboxamide derivatives against Haemonchus contortus.

Jiao Y, Preston S, Song H, Jabbar A, Liu Y, Baell J, Hofmann A, Hutchinson D, Wang T, Koehler AV, Fisher GM, Andrews KT, Laleu B, Palmer MJ, Burrows JN, Wells TNC, Wang Q, Gasser RB.

Parasit Vectors. 2017 May 31;10(1):272. doi: 10.1186/s13071-017-2191-8.

14.

Susceptibility Testing of Medically Important Parasites.

Genetu Bayih A, Debnath A, Mitre E, Huston CD, Laleu B, Leroy D, Blasco B, Campo B, Wells TNC, Willis PA, Sjö P, Van Voorhis WC, Pillai DR.

Clin Microbiol Rev. 2017 Jul;30(3):647-669. doi: 10.1128/CMR.00111-16. Review.

15.

Erratum to: New developments in anti-malarial target candidate and product profiles.

Burrows JN, Duparc S, Gutteridge WE, van Huijsduijnen RH, Kaszubska W, Macintyre F, Mazzuri S, Möhrle JJ, Wells TNC.

Malar J. 2017 Apr 18;16(1):151. doi: 10.1186/s12936-017-1809-9. No abstract available.

16.

Managing intellectual property to develop medicines for the world's poorest.

Fonteilles-Drabek S, Reddy D, Wells TN.

Nat Rev Drug Discov. 2017 Apr;16(4):223-224. doi: 10.1038/nrd.2017.24. Epub 2017 Feb 24.

PMID:
28232725
17.

New developments in anti-malarial target candidate and product profiles.

Burrows JN, Duparc S, Gutteridge WE, Hooft van Huijsduijnen R, Kaszubska W, Macintyre F, Mazzuri S, Möhrle JJ, Wells TNC.

Malar J. 2017 Jan 13;16(1):26. doi: 10.1186/s12936-016-1675-x. Review. Erratum in: Malar J. 2017 Apr 18;16(1):151.

18.

Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles.

Williamson AE, Ylioja PM, Robertson MN, Antonova-Koch Y, Avery V, Baell JB, Batchu H, Batra S, Burrows JN, Bhattacharyya S, Calderon F, Charman SA, Clark J, Crespo B, Dean M, Debbert SL, Delves M, Dennis AS, Deroose F, Duffy S, Fletcher S, Giaever G, Hallyburton I, Gamo FJ, Gebbia M, Guy RK, Hungerford Z, Kirk K, Lafuente-Monasterio MJ, Lee A, Meister S, Nislow C, Overington JP, Papadatos G, Patiny L, Pham J, Ralph SA, Ruecker A, Ryan E, Southan C, Srivastava K, Swain C, Tarnowski MJ, Thomson P, Turner P, Wallace IM, Wells TN, White K, White L, Willis P, Winzeler EA, Wittlin S, Todd MH.

ACS Cent Sci. 2016 Oct 26;2(10):687-701. Epub 2016 Sep 14.

19.

Screening of the 'Pathogen Box' identifies an approved pesticide with major anthelmintic activity against the barber's pole worm.

Preston S, Jiao Y, Jabbar A, McGee SL, Laleu B, Willis P, Wells TNC, Gasser RB.

Int J Parasitol Drugs Drug Resist. 2016 Dec;6(3):329-334. doi: 10.1016/j.ijpddr.2016.07.004. Epub 2016 Jul 28. Review.

20.

Open data in drug discovery and development: lessons from malaria.

Wells TN, Willis P, Burrows JN, Hooft van Huijsduijnen R.

Nat Rev Drug Discov. 2016 Oct;15(10):661-2. doi: 10.1038/nrd.2016.154. Epub 2016 Aug 12.

PMID:
27516171
21.

Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development.

McCarthy JS, Marquart L, Sekuloski S, Trenholme K, Elliott S, Griffin P, Rockett R, O'Rourke P, Sloots T, Angulo-Barturen I, Ferrer S, Jiménez-Díaz MB, Martínez MS, Hooft van Huijsduijnen R, Duparc S, Leroy D, Wells TN, Baker M, Möhrle JJ.

Antimicrob Agents Chemother. 2016 May 23;60(6):3669-75. doi: 10.1128/AAC.02883-15. Print 2016 Jun.

22.

Tools and Strategies for Malaria Control and Elimination: What Do We Need to Achieve a Grand Convergence in Malaria?

Hemingway J, Shretta R, Wells TN, Bell D, Djimdé AA, Achee N, Qi G.

PLoS Biol. 2016 Mar 2;14(3):e1002380. doi: 10.1371/journal.pbio.1002380. eCollection 2016 Mar. Review.

23.

Profile of William C. Campbell, Satoshi Ōmura, and Youyou Tu, 2015 Nobel Laureates in Physiology or Medicine.

Van Voorhis WC, Hooft van Huijsduijnen R, Wells TN.

Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15773-6. doi: 10.1073/pnas.1520952112. Epub 2015 Dec 22. No abstract available.

24.

A Proposed Target Product Profile and Developmental Cascade for New Cryptosporidiosis Treatments.

Huston CD, Spangenberg T, Burrows J, Willis P, Wells TN, van Voorhis W.

PLoS Negl Trop Dis. 2015 Oct 8;9(10):e0003987. doi: 10.1371/journal.pntd.0003987. eCollection 2015 Oct. No abstract available.

25.

Ferroquine: welcome to the next generation of antimalarials.

Wells TN, Hooft van Huijsduijnen R.

Lancet Infect Dis. 2015 Dec;15(12):1365-6. doi: 10.1016/S1473-3099(15)00148-6. Epub 2015 Sep 3. No abstract available.

PMID:
26342426
26.

Malaria medicines: a glass half full?

Wells TN, Hooft van Huijsduijnen R, Van Voorhis WC.

Nat Rev Drug Discov. 2015 Jun;14(6):424-42. doi: 10.1038/nrd4573. Epub 2015 May 22. Review.

PMID:
26000721
27.

Orally active antischistosomal early leads identified from the open access malaria box.

Ingram-Sieber K, Cowan N, Panic G, Vargas M, Mansour NR, Bickle QD, Wells TN, Spangenberg T, Keiser J.

PLoS Negl Trop Dis. 2014 Jan 9;8(1):e2610. doi: 10.1371/journal.pntd.0002610. eCollection 2014.

28.

Anticancer properties of distinct antimalarial drug classes.

Hooft van Huijsduijnen R, Guy RK, Chibale K, Haynes RK, Peitz I, Kelter G, Phillips MA, Vennerstrom JL, Yuthavong Y, Wells TN.

PLoS One. 2013 Dec 31;8(12):e82962. doi: 10.1371/journal.pone.0082962. eCollection 2013.

29.

Discovering and developing new medicines for malaria control and elimination.

Wells TN.

Infect Disord Drug Targets. 2013 Aug;13(4):292-302.

PMID:
24304355
30.

Open source drug discovery - a limited tutorial.

Robertson MN, Ylioja PM, Williamson AE, Woelfle M, Robins M, Badiola KA, Willis P, Olliaro P, Wells TN, Todd MH.

Parasitology. 2014 Jan;141(1):148-57. doi: 10.1017/S0031182013001121. Epub 2013 Aug 28. Review.

31.

Antimalarial drug discovery - the path towards eradication.

Burrows JN, Burlot E, Campo B, Cherbuin S, Jeanneret S, Leroy D, Spangenberg T, Waterson D, Wells TN, Willis P.

Parasitology. 2014 Jan;141(1):128-39. doi: 10.1017/S0031182013000826. Epub 2013 Jul 17. Review.

32.

The open access malaria box: a drug discovery catalyst for neglected diseases.

Spangenberg T, Burrows JN, Kowalczyk P, McDonald S, Wells TN, Willis P.

PLoS One. 2013 Jun 17;8(6):e62906. doi: 10.1371/journal.pone.0062906. Print 2013.

33.

Designing the next generation of medicines for malaria control and eradication.

Burrows JN, van Huijsduijnen RH, Möhrle JJ, Oeuvray C, Wells TN.

Malar J. 2013 Jun 6;12:187. doi: 10.1186/1475-2875-12-187. Review.

34.

Malaria in South America: a drug discovery perspective.

Cruz LR, Spangenberg T, Lacerda MV, Wells TN.

Malar J. 2013 May 24;12:168. doi: 10.1186/1475-2875-12-168. Review.

35.

Glycosaminoglycan analogs as a novel anti-inflammatory strategy.

Severin IC, Soares A, Hantson J, Teixeira M, Sachs D, Valognes D, Scheer A, Schwarz MK, Wells TN, Proudfoot AE, Shaw J.

Front Immunol. 2012 Oct 16;3:293. doi: 10.3389/fimmu.2012.00293. eCollection 2012.

36.

A high-throughput assay for the identification of malarial transmission-blocking drugs and vaccines.

Delves MJ, Ramakrishnan C, Blagborough AM, Leroy D, Wells TN, Sinden RE.

Int J Parasitol. 2012 Oct;42(11):999-1006. doi: 10.1016/j.ijpara.2012.08.009. Epub 2012 Sep 27.

PMID:
23023046
37.

The global pipeline of new medicines for the control and elimination of malaria.

Anthony MP, Burrows JN, Duparc S, Moehrle JJ, Wells TN.

Malar J. 2012 Sep 7;11:316. doi: 10.1186/1475-2875-11-316. Review.

38.

A framework for assessing the risk of resistance for anti-malarials in development.

Ding XC, Ubben D, Wells TN.

Malar J. 2012 Aug 22;11:292. doi: 10.1186/1475-2875-11-292.

39.

Natural products as starting points for future anti-malarial therapies: going back to our roots?

Wells TN.

Malar J. 2011 Mar 15;10 Suppl 1:S3. doi: 10.1186/1475-2875-10-S1-S3. Review.

40.

The state of the art in anti-malarial drug discovery and development.

Burrows JN, Chibale K, Wells TN.

Curr Top Med Chem. 2011;11(10):1226-54. Review.

PMID:
21401508
41.

Microbiology. Is the tide turning for new malaria medicines?

Wells TN.

Science. 2010 Sep 3;329(5996):1153-4. doi: 10.1126/science.1194923. No abstract available.

PMID:
20813940
42.
43.

Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination.

Wells TN, Burrows JN, Baird JK.

Trends Parasitol. 2010 Mar;26(3):145-51. doi: 10.1016/j.pt.2009.12.005. Epub 2010 Feb 3. Review.

PMID:
20133198
44.

Kinetics of chemokine-glycosaminoglycan interactions control neutrophil migration into the airspaces of the lungs.

Tanino Y, Coombe DR, Gill SE, Kett WC, Kajikawa O, Proudfoot AE, Wells TN, Parks WC, Wight TN, Martin TR, Frevert CW.

J Immunol. 2010 Mar 1;184(5):2677-85. doi: 10.4049/jimmunol.0903274. Epub 2010 Feb 1.

45.

New medicines to improve control and contribute to the eradication of malaria.

Wells TN, Alonso PL, Gutteridge WE.

Nat Rev Drug Discov. 2009 Nov;8(11):879-91. doi: 10.1038/nrd2972. Epub 2009 Oct 16. Review.

PMID:
19834482
46.

The global portfolio of new antimalarial medicines under development.

Olliaro P, Wells TN.

Clin Pharmacol Ther. 2009 Jun;85(6):584-95. doi: 10.1038/clpt.2009.51. Epub 2009 Apr 29. Review.

PMID:
19404247
47.

Ticks produce highly selective chemokine binding proteins with antiinflammatory activity.

Déruaz M, Frauenschuh A, Alessandri AL, Dias JM, Coelho FM, Russo RC, Ferreira BR, Graham GJ, Shaw JP, Wells TN, Teixeira MM, Power CA, Proudfoot AE.

J Exp Med. 2008 Sep 1;205(9):2019-31. doi: 10.1084/jem.20072689. Epub 2008 Aug 4.

48.

An engineered monomer of CCL2 has anti-inflammatory properties emphasizing the importance of oligomerization for chemokine activity in vivo.

Handel TM, Johnson Z, Rodrigues DH, Dos Santos AC, Cirillo R, Muzio V, Riva S, Mack M, Déruaz M, Borlat F, Vitte PA, Wells TN, Teixeira MM, Proudfoot AE.

J Leukoc Biol. 2008 Oct;84(4):1101-8. doi: 10.1189/jlb.0108061. Epub 2008 Jul 28.

49.

Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy.

Ojo KK, Gillespie JR, Riechers AJ, Napuli AJ, Verlinde CL, Buckner FS, Gelb MH, Domostoj MM, Wells SJ, Scheer A, Wells TN, Van Voorhis WC.

Antimicrob Agents Chemother. 2008 Oct;52(10):3710-7. doi: 10.1128/AAC.00364-08. Epub 2008 Jul 21.

50.

Molecular cloning and characterization of a highly selective chemokine-binding protein from the tick Rhipicephalus sanguineus.

Frauenschuh A, Power CA, Déruaz M, Ferreira BR, Silva JS, Teixeira MM, Dias JM, Martin T, Wells TN, Proudfoot AE.

J Biol Chem. 2007 Sep 14;282(37):27250-8. Epub 2007 Jul 19.

Supplemental Content

Loading ...
Support Center